## novœure®

# a global oncology company

Founded in 2000, Novocure develops and commercializes an innovative therapy for the treatment of solid tumors: Tumor Treating Fields (TTFields).

## novœure®

#### at a glance

30,000 PATIENTS TREATED TO DATE





IALS

FDA APPROVED

as of February 2024


Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, TTFields. **TTFields** are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms, including disruption of mitosis, enhancement of anti-tumor immunity, interference with cell movement and migration and downregulation of DNA damage response.

In 2000, our founder, Professor Yoram Palti, sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.

"Nobody understood what I was doing," Professor Palti said of his early development of TTFields.

Professor Palti's initial research from his basement laboratory evolved to become Novocure – an international oncology company with operations in North America, Europe, the Middle East and Asia.

Today, our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. We have ongoing or completed clinical studies investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, ovarian cancer and pancreatic cancer.



#### our mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields.

#### our values

INNOVATION	FOCUS	DRIVE
COURAGE	TRUST	EMPATHY



TTFIELDS THERAPY IS A PLATFORM THERAPY, WITH SIGNIFICANT POTENTIAL FOR VERSATILITY ACROSS SOLID TUMOR TYPES AND LINES OF THERAPY.

"We are diligently working to reach additional patients in our current markets, expand into new markets, enhance our products and treat patients in new indications."

- William Doyle, Novocure's Executive Chairman



 $\nabla$ 

Our portable Tumor Treating Fields therapy is designed to be delivered continuously to allow patients to go about their daily activities while receiving treatment.



Tumor Treating Fields are generated via pairs of transducer arrays placed directly on the skin's surface in the region surrounding the tumor.

X



## our pipeline

				Δ	<b></b>	
		Trial	TTFields therapy +	Phase 2	Phase 3	Approved
CNS PROGRAM	newly diagnosed glioblastoma	EF-14	temozolomide			
		TRIDENT	temozolomide + radiation		FINAL DATA PENDING	
		KEYNOTE D58	temozolomide + pembrolizumab		PLANNED	
	recurrent glioblastoma	EF-11	monotherapy			
THORACIC CANCER PROGRAM	brain metastasis	METIS	monotherapy		FINAL DATA PENDING	
	non-small cell lung cancer	EF-15	pemetrexed	COMPLETED		
		LUNAR	docetaxel or PD-L1 inhibitor		COMPLETED	
		LUNAR-2	pembrolizumab + chemotherapy			
		KEYNOTE B36	pembrolizumab	ENROLLING		
	mesothelioma	STELLAR	pemetrexed + (cisplatin or carboplatin)			
ABDOMINAL CANCER PROGRAM	pancreatic cancer	PANOVA	nab-paclitaxel + gemcitabine	COMPLETED		
		PANOVA-3	nab-paclitaxel + gemcitabine		FINAL DATA PENDING	
		PANOVA-4	atezolizumab + nab-paclitaxel + gemcitabine	ENROLLING		

# novœure®

### our global footprint

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. Our active markets are below.



"We are committed to making our therapy available to all the patients who may benefit. We have a unique opportunity to make an even larger impact as we bring our therapy to more patients throughout the world."

- Asaf Danziger, CEO





For more information, visit **novocure.com** Follow **@Novocure** on **in** and X

Patient images reflect the health status of the patient(s) at the time each photo was taken. ©2024 Novocure GmbH. All Rights Reserved. Novocure is a registered trademark of Novocure GmbH. GLB-COMM-00488 March 2023 v2.0